Table 2.
Characteristics of high-risk patients with SARS-CoV-2 infection within 180 days of T-C.
| Patients | Diagnosis | Age (years)* | Gender | # T-C doses | Predominant variant at the time of infection (27) | Time from T-C to SARS-CoV-2 infection (days)* | Vaccinated prior to SARS-CoV-2 infection | Severe COVID-19 |
|---|---|---|---|---|---|---|---|---|
| 1 | relapsed ALL | 14-17 | M | 1 | BA.5 | 100-130 | Yes | No |
| 2 | AML | 14-17 | F | 1 | BA.5 | 100-130 | No | No |
| 3 | AML | 14-17 | F | 1 | BA.5 | 70-100 | Yes | No |
| 4 | MPL | 14-17 | M | 1 | BA.5 | 120-150 | Yes | No |
| 5 | AML | 13-16 | M | 1 | BQ.1 | 60-90 | Yes | No |
| 6 | ALL | 12-15 | M | 2 | BA.5 | 15-30 | Yes | No |
| 7^ | AML | 17-20 | M | 2 | BA.5 | 80-110 | Yes | Yes |
^ Patient had a second episode of SARS-CoV-2 between 120-150 days after first dose of T-C. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MPL, mixed phenotype leukemia. * To ensure that data was unidentifiable age and time of SARS-CoV-2 infection from T-C dose are presented as ranges.